FDA Accepts REGEN-COV® (casirivimab and imdevimab) for Priority Review for Treatment and Prophylaxis of COVID-19

/PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the U.S. Food and Drug Administration (FDA) has accepted for priority...

Related Keywords

Japan ,United States ,India ,United Kingdom ,Brazil ,South Africa ,Colombia ,Canada ,Switzerland ,September Regeneron ,Georged Yancopoulos ,Tammy Allen ,Regeneron Velocimmune ,Vesna Tosic ,Twitter ,Human Service Office Of The ,Regeneron Velocimmune Technology ,Nasdaq ,Teva Pharmaceutical Industries Ltd ,Department Of Health ,European Union ,Pharmaceuticals Inc ,Centers For Disease ,Regeneron Pharmaceuticals Inc ,Biomedical Advanced Research ,Regeneron Genetics Center ,Human Services ,Us Department Of Health ,Drug Administration ,Development Authority ,Exchange Commission ,European Medicines Agency ,National Infusion Center Association ,Biologics License Application ,Marketing Authorization Application ,Emergency Use Authorization ,National Infusion Center ,Human Service Office ,Assistant Secretary ,Fact Sheet ,Chief Scientific Officer George ,Authorized Use ,Exposure Prophylaxis ,Disease Control ,Post Exposure Prophylaxis ,Healthcare Providers ,Dear Healthcare Provider Letter ,Patient Fact ,Identifying High Risk ,Antiviral Resistance ,Including Anaphylaxis ,Infusion Related Reactions ,Subcutaneous Dosing ,Monitoring Recommendations ,Specific Populations ,Looking Statements ,Regeneron Pharmaceuticals ,Product Candidates ,Biologics License Applications ,Marketing Authorization Applications ,Teva Pharmaceutical Industries ,Nc ,